News

HSG Scholarship Winners Receive Funding to Attend Premier Huntington’s Disease Conference

August 22nd, 2018 Chris Markham The Huntington Study Group (HSG) announces the 2018 CME4HD Online scholarship winners who have been awarded funding to attend its renowned annual meeting, HSG 2018: Unlocking HD. Maryluz Camargo Mendoza, Ph.D, associate professor at the National University of Colombia, Bogota, has received a scholarship for referring 49 people who successfully completed five CME4HD Online modules.
+ Read More

Huntington Study Group Welcomes New Leadership May 1

March 13th, 2018 Heather Hare The Huntington Study Group (HSG) is pleased to announce that Andrew Feigin, MD, and Elise Kayson, MS, ANP, have been elected as the chair and co-chair, respectively, of HSG, a world-wide network of Huntington disease (HD) researchers. Both Feigin and Kayson have dedicated their careers to the clinical care of patients and families and research
+ Read More

New HD Insights Is Out (Vol. 19)

February 27th, 2018 Heather Hare   The new issue of HD Insights (Vol. 19) is out. Click here to read the latest news in HD research. In this issue: First Gene Therapy Approved for Inherited Disease Is Approved Drug Successfully Lowers Mutant Huntingtin Protein Meet the Foundation: Fox Family Foundation Career Opportunity: Clinical Fellowship in Huntington Disease Research at UBC
+ Read More

HSG Leadership Election Results

February 19th, 2018 Heather Hare On behalf of the HSG Nominating Committee, it is with great pleasure that we announce that Andrew Feigin and Elise Kayson have won the run-off election for the HSG Chair and Co-Chair positions. We thank all of the candidates who ran for these positions and salute their enthusiasm and commitment to the entire election process.
+ Read More

2018 HSG Election

January 9th, 2018 Heather Hare Dear HSG Members, Below is the content of an email that all HSG members should have received today. If you didn’t receive it, please check your spam folder and mark it a “safe sender” so you receive future important communications from HSG. If you have any trouble logging in, please contact HSG at +1 800-487-7671
+ Read More

Ionis and Roche announce promising news on the Ionis-HTTRx trial

December 12th, 2017 Heather Hare Ionis and Roche announced Monday, Dec. 11, that the Phase 1/2a Ionis-HTTRx trial reported no significant safety issues among participants. In addition, cerebral spinal fluid collected from participants during the trial showed a dose-dependent reduction in mutant huntingtin proteins in the fluid. For more information, read the HD Buzz article about the announcement. More details
+ Read More

Welcome new staff member, members of leadership team

July 21st, 2017 Heather Hare The Huntington Study Group is pleased to announce a new staff member and new members of the leadership team. Anne Van Dusen, CHC, is HSG’s new Director of Education & Special Programs, Sarah Noonberg, MD, PhD, replaces Mike Poole, MD, on the executive committee, and Christopher Beck, PhD, replaces David Oakes, PhD, as HSG’s Director
+ Read More

Overnight Switch from Tetrabenazine to Deutetrabenazine Safe, Trial Shows

July 11th, 2017 Heather Hare JAMA Neurology paper published today from ARC-HD Trial People with Huntington disease-associated chorea can safely convert overnight from tetrabenazine to deutetrabenazine (brand name: Austedo), according to the results of the Alternatives for Reducing Chorea in Huntington Disease (ARC-HD) trial published yesterday in JAMA Neurology. The Phase III open-label, single-arm switch cohort of the trial was
+ Read More

FDA Approves Second Drug for Huntington Disease Symptom

April 3rd, 2017 Heather Hare The U.S. Food and Drug Administration (FDA) today approved SD-809 (deutetrabenazine), the second drug approved for use in the United States to treat chorea in Huntington disease (HD), a rare, inherited neurodegenerative disorder. The approval was based on positive results from the First-HD study, a Phase 3 clinical trial which was led by the Huntington
+ Read More